Increased risk of high‐grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy
- 3 March 2009
- Vol. 115 (6), 1286-1299
- https://doi.org/10.1002/cncr.24120
Abstract
BACKGROUND: The addition of epidermal growth factor receptor (EGFR) inhibitors to radiotherapy has produced increased locoregional control and has reduced mortality from various solid tumors with few additional toxicities. Although anecdotal reports have suggested increased radiation dermatitis, the overall effect of these regimens on dermatologic toxicities has not been ascertained. METHODS: Dermatologic toxicity data were analyzed from abstracts presented at the annual meetings of the American Society of Clinical Oncology, the American Society of Therapeutic Radiology and Oncology, Cochrane Collaboration, MEDLINE, and EMBASE databases. Phase 1, 2, and 3 trials that reported on radiation dermatitis, rash, and mucositis were included. Collaborative group, phase 3, randomized radiotherapy and chemoradiation trials served as controls. The summary incidence rate and relative risk were calculated using a random‐effects or fixed‐effects model, depending on the heterogeneity of included studies. RESULTS: The summary incidence of high‐grade radiation dermatitis in patients who received radiation plus EGFR inhibitors was 31.3% (95% confidence interval [95% CI], 17.7%‐49.1%), rash in 16.1% (95% CI, 12.8%‐20.1%), and mucositis occurred in 52.7% (95% CI, 38.1%‐66.9%). When the combination of radiotherapy plus EGFR inhibitors was compared with radiation alone, the risk ratio for radiation dermatitis was 2.38 (95% CI, 1.8‐3.2; P < .001), rash was 3.01 (95% CI, 2.0‐4.6; P < .001), for mucositis it was 1.76 (95% CI, 1.5‐2.0; P < .001), suggesting that there was an increased risk of dermatologic toxicities with the combined regimen. CONCLUSIONS: EGFR inhibitors combined with radiation were associated with a significant increase in the risk for high‐grade radiation dermatitis, rash, and mucositis. Although increased rash is expected with EGFR inhibitors, in‐field dermatitis and mucositis represent new safety concerns. Improved reporting and management strategies are critical for quality of life and the optimization of radiation plus EGFR inhibitor protocols. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Cetuximab is Effective, but more Toxic than Reported in the Bonner TrialClinical Oncology, 2008
- Development and Management of Severe Cutaneous Side Effects in Head-and-Neck Cancer Patients during Concurrent Radiotherapy and CetuximabStrahlentherapie Und Onkologie, 2008
- Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234)International Journal of Radiation Oncology*Biology*Physics, 2007
- Phase I Trial of Pemetrexed in Combination with Cetuximab and Concurrent Radiotherapy in Head and Neck Cancer (HNC)International Journal of Radiation Oncology*Biology*Physics, 2007
- Early Toxicity and Response Data From a Phase II Trial of Weekly Cetuximab, CBDCA, Paclitaxel, and Daily RT in Patients With Locally Advanced SCCHNInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Phase I/II Study of Concurrent Erlotinib and Chemoradiation for Post-Resected Locally Advanced Squamous Head and Neck Cancer (HNSCC): A Gicor StudyInternational Journal of Radiation Oncology*Biology*Physics, 2007
- RTOG 0324: A Phase II Study of Cetuximab (C225) in Combination With Chemoradiation (CRT) in Patients (PTS) With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): Correlation Between EGFR Expression and the Patients' OutcomeInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Randomized Phase II Trial of Radiotherapy With or Without Erlotinib in Patients With Locally Advanced or Unresectable Non-Small Cell Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Severe Cutaneous Reaction during Radiation Therapy with Concurrent CetuximabNew England Journal of Medicine, 2007
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006